Search results
Results from the WOW.Com Content Network
Antihypertensive agents comprise multiple classes of compounds that are intended to manage hypertension (high blood pressure). Antihypertensive therapy aims to maintain a blood pressure goal of <140/90 mmHg in all patients, as well as to prevent the progression or recurrence of cardiovascular diseases (CVD) in hypertensive patients with established CVD. [2]
Renin inhibitors can therefore effectively reduce hypertension. Aliskiren (developed by Novartis) is a renin inhibitor which has been approved by the U.S. FDA for the treatment of hypertension. [ 44 ]
It is a humanized monoclonal antibody functioning as a terminal complement inhibitor. [13] It binds to the complement C5 protein and inhibits activation of the complement system, a part of the body's immune system. [16]
Avacincaptad pegol is a complement inhibitor. [1] Avacincaptad pegol was approved for medical use in the United States in August 2023. [2] [3] [4] Medical uses.
This list was created from the NCI Thesaurus This page was last edited on 9 February 2024, at 00:17 (UTC). Text ... List of phosphodiesterase inhibitors.
In 2007, aliskiren was approved by the US Food and Drug Administration and the European Medicines Agency as a treatment for hypertension. [7] A systematic review by the Cochrane Hypertension group found the maximum recommended dose of aliskiren produced an appreciable decline in blood pressure over placebo. [16]
Ravulizumab, sold under the brand name Ultomiris, is a humanized monoclonal antibody complement inhibitor medication designed for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome. It is designed to bind to and prevent the activation of Complement component 5 (C5). [8] [7]
Moexipril was an angiotensin converting enzyme inhibitor (ACE inhibitor) [1] used for the treatment of hypertension and congestive heart failure. Moexipril can be administered alone or with other antihypertensives or diuretics. [2] It works by inhibiting the conversion of angiotensin I to angiotensin II. [3]